TG Therapeutics, Inc. (0VGI.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 4.39B |
| Enterprise Value | 4.56B |
| P/E Ratio | 16.96 |
| PEG Ratio | 0.02 |
| Price/Sales Ratio | 11.79 |
| Price/Book Ratio | 13.36 |
| Enterprise/Revenue | 12.23 |
| Enterprise/EBITDA | 57.05 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | 0.66 |
| Operating Margin | 0.21 |
AD
Management Effectiveness
| Return On Assets | 0.3 |
| Return On Equity | 0.87 |
Income Statement
| Revenue | 616.29M |
| Revenue/Share | 4.85 |
| Gross Profit | 515.57M |
| EBITDA | 125.32M |
| Net Income | 447.18M |
| Diluted EPS | 2.77 |
Balance Sheet
| Total Cash | 514.43M |
| Total Cash/Share | 3.56 |
| Total Debt | 753.56M |
| Total Debt/Equity | 1.29 |
| Current Ratio | 5.81 |
| Book Value Per Share | 4.04 |
Price History
| 52-Week Change | 30.57 |
| 52-Week High | 36.65 |
| 52-Week Low | 6.47 |
| Moving Average 50 Days | 16.04 |
| Moving Average 200 Days | 15.15 |
Statistics
| Average Volume | 12,871 |
| Shares Outstanding | 143.75M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
